CM
ROIV icon

Capula Management’s Roivant Sciences ROIV Stock Holding History

Capula Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,574
Closed -$278K – 823
2025
Q1 		$278K Buy
+27,574
New +$298K ﹤0.01% 419
2024
Q4 		– Sell
-79,733
Closed -$920K – 569
2024
Q3 		$920K Sell
79,733
-2,071
-3% -$23.6K 0.01% 150
2024
Q2 		$865K Buy
+81,804
New +$896K 0.01% 173

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Capula Management's ROIV Position: Q2 2025 in Review

Capula Management sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 27,574 shares — an estimated $278K sold.

Capula Management first reported a position in ROIV in Q2 2024 and held it in 3 quarters. The position peaked at $920K in Q3 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

  • Capula Management reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
  • Capula Management sold 27,574 Roivant Sciences shares in Q2 2025, an estimated $278K.
  • Capula Management first reported a position in Roivant Sciences in Q2 2024 and held it in 3 quarters.
  • Capula Management's Roivant Sciences position peaked at $920K in Q3 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.